Compare

Galectin Therapeutics/$GALT

1D1W1M3M6MYTD1Y5YMAX

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Ticker
$GALT
Sector
Health
Primary listing
NASDAQ
Employees
9
Headquarters
Norcross, United States
Website
galectintherapeutics.com

GALT Metrics

BasicAdvanced
$367M
-
-$0.43
0.39
-

What the Analysts think about GALT

Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
Analyst projections of the future price of Galectin Therapeutics stock.

Bulls say / Bears say

Galectin says it has agreed key Phase 3 design and regulatory elements with the FDA, and submitted the registrational protocol on 6 October. This gives belapectin a clearer route into a pivotal trial, though it does not establish that the FDA will approve the protocol or that the drug will work. (GlobeNewswire)
In NAVIGATE, the 2 mg/kg dose showed a numerical reduction in new varices in the full analysis set and a statistically significant reduction in the per-protocol group. Supportive fibrosis-marker results and a favourable safety profile offer clinical evidence for the Phase 3 case, although these findings do not erase the trial’s primary-endpoint failure. (Galectin Therapeutics)
The company converted about $105.8 million of debt and accrued interest into equity, removing most of its chairman-related debt and materially improving its balance-sheet structure. That could leave more financial flexibility to advance belapectin, even though the share issuance diluted existing holders. (GlobeNewswire)
NAVIGATE missed its main goal of showing a statistically significant reduction in new varices in the overall trial population. The positive per-protocol result is therefore not conclusive evidence that belapectin works. (Liver Disease News)
Galectin had $13.3 million of cash at 30 June and said cash plus its available credit line should fund planned operations only through June 2027. Its filing also warned that it needs additional capital and raised substantial doubt about its ability to continue as a going concern, leaving the costly Phase 3 programme exposed to funding risk. (Galectin Therapeutics)
The debt conversion involved issuing 34.4 million new shares to the chairman, diluting existing shareholders. The balance-sheet benefit came at a material cost to each existing share’s ownership stake. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.

GALT Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

GALT Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

GALT News

AllArticlesVideos

20 stocks likely to lose money even if the bull market continues

Market Watch1 month ago

Funds containing GALT

AllEURGBP
Funds
Fund name
Fund size
$GALT weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.00%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.